Medicare AdvantageCoverageMedium impact
MA08.138e, Tafasitamab-cxix (Monjuvi®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Aug 18, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.138e for Tafasitamab-cxix (Monjuvi®) has been updated with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects billing and coverage requirements for this oncology medication used in lymphoma treatment.
Action Required
By August 18, 2025: Billing and clinical teams should review the updated policy MA08.138e for Tafasitamab-cxix (Monjuvi®) to understand new medical necessity criteria and coding requirements. Update prior authorization workflows and documentation requirements for Medicare Advantage patients receiving this lymphoma treatment. Ensure compliance with revised guidelines to prevent claim denials.